Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025

BETHESDA, Md., April 25, 2025 /PRNewswire/ -- Precision Biologics, Inc. reports preclinical development and characterization of a novel ADC using its anti-core 2 O-glycans anti-human carcinoma mAb PB-223 will be presented in a poster at the American Association for Cancer Research (AACR)...